데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
1402-82-0CCC(C)CCCCC/C=C/CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)[C@@H]1NC(=O)[C@H]2CCCCN2C1=O)C(C)C)[C@H](C)N)[C@@H](C)C(=O)OXBNDESPXQUOOBQ-LSMLZNGOSA-N1402-82-0DTXSID101017657CHEMBL2103921안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
용도Amphomycin is a lipopeptide antibiotic produced by Streptomycetes and Actinoplanes, initially reported by researchers at Bristol-Myers in 1953 from Streptomyces canus. Amphomycin was marketed as a complex of closely related analogues in the 1950s and 1960s. Structure elucidation was not completed until 2000. Amphomycin is active against Gram positive bacteria, inhibiting peptidoglycan synthesis and blocking cell wall development. Amphomycin is closely related to a number of “lost” antibiotics, aspartocin, crystallomycin, glumamycin, friulimicin, laspartocin, tsushimycin and zaomycin. Interest in amphomycin was re-awakened with the discovery of friulimicin activity against antibiotic resistant strains.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…